Elicio Therapeutics Files 8-K
Ticker: ELTX · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-reporting
TL;DR
ELIO filed an 8-K, standard update, nothing major.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on September 17, 2025, reporting on other events and financial statements. The company, formerly known as Angion Biomedica Corp. until February 28, 2014, is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing provides an update on Elicio Therapeutics' corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing that does not appear to contain significant new information or material changes.
Key Numbers
- 001-39990 — SEC File Number (Identifies the company's filing history)
- 11-3430072 — IRS Employer Identification No. (Tax identification for the company)
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- September 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Boston, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report for Elicio Therapeutics, Inc., covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was Elicio Therapeutics, Inc. formerly known as Angion Biomedica Corp.?
Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp. until February 28, 2014.
Where are Elicio Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Elicio Therapeutics, Inc. are located at 451 D Street, 5th Floor, Boston, Massachusetts 02210.
What is the company's state of incorporation?
Elicio Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Elicio Therapeutics, Inc.?
The SEC file number for Elicio Therapeutics, Inc. is 001-39990.
Filing Stats: 1,077 words · 4 min read · ~4 pages · Grade level 9.9 · Accepted 2025-09-17 08:16:34
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share ELTX The Nasdaq
Filing Documents
- d38971d8k.htm (8-K) — 39KB
- d38971dex991.htm (EX-99.1) — 30KB
- d38971dex992.htm (EX-99.2) — 21KB
- g38971ex99_2s10g1.jpg (GRAPHIC) — 140KB
- g38971ex99_2s11g1.jpg (GRAPHIC) — 70KB
- g38971ex99_2s12g1.jpg (GRAPHIC) — 58KB
- g38971ex99_2s1g1.jpg (GRAPHIC) — 59KB
- g38971ex99_2s2g1.jpg (GRAPHIC) — 103KB
- g38971ex99_2s3g1.jpg (GRAPHIC) — 142KB
- g38971ex99_2s4g1.jpg (GRAPHIC) — 73KB
- g38971ex99_2s5g1.jpg (GRAPHIC) — 107KB
- g38971ex99_2s6g1.jpg (GRAPHIC) — 126KB
- g38971ex99_2s7g1.jpg (GRAPHIC) — 109KB
- g38971ex99_2s8g1.jpg (GRAPHIC) — 120KB
- g38971ex99_2s9g1.jpg (GRAPHIC) — 94KB
- 0001193125-25-205522.txt ( ) — 1880KB
- eltx-20250917.xsd (EX-101.SCH) — 3KB
- eltx-20250917_lab.xml (EX-101.LAB) — 18KB
- eltx-20250917_pre.xml (EX-101.PRE) — 11KB
- d38971d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated September 17, 2025 99.2 Corporate Presentation, dated September 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 17, 2025 Elicio Therapeutics, Inc. By: /s/ Robert Connelly Robert Connelly President and Chief Executive Officer (Principal Executive Officer) 4